IGC Pharma, Inc. (FRA:IGS1)
Germany · Delayed Price · Currency is EUR 0.2740
0.00 (0.00%)
At close: Nov 28, 2025
IGC Pharma Company Description
IGC Pharma, Inc., a clinical stage pharmaceutical company, develops treatments for Alzheimer’s disease in the United States and Colombia.
The company’s lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer’s.
Its pre-clinical stage product candidate includes TGR-63, IGC-M3, and LMP to treat Alzheimer’s disease; IGC-1C for the treatment of metabolic disorders and Alzheimer’s disease; and IGC-1A to treat metabolic disorders.
The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023.
IGC Pharma, Inc. was incorporated in 2005 and is headquartered in Potomac, Maryland.
IGC Pharma, Inc.
| Country | United States |
| Founded | 2005 |
| Industry | Pharmaceutical Preparations |
| Employees | 70 |
| CEO | Ram Mukunda |
Contact Details
Address: 10224 Falls Road Potomac, Maryland 20854 United States | |
| Phone | 301 983 0998 |
| Website | igcpharma.com |
Stock Details
| Ticker Symbol | IGS1 |
| Exchange | Frankfurt Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Ram Mukunda | Chief Executive Officer |
| Claudia Grimaldi | Chief Financial Officer |
| Benysh Qureshi | Chief Operating Officer |